(Updates with stock price movement in the headline and first paragraph.)
Tenaya Therapeutics (TNYA) shares plunged nearly 51% in recent trading on Tuesday after initial data for this gene therapy study indicated a manageable safety profile with isolated elevations in liver enzymes of the first three dosed patients.
The company said Tuesday that preliminary data from the first cohort in a phase 1b/2 trial showed that its TN-201 gene therapy was well tolerated, with no cardiac toxicities or severe adverse effects.
TN-201 is being developed for the potential treatment of MYBPC3-associated hypertrophic cardiomyopathy, a condition caused by insufficient levels of myosin-binding protein C, the company said.
Tenaya said the initial results demonstrated "readily detectable vector DNA in the heart, evidence of transgene RNA expression, and increasing TN-201 mRNA and MyBP-C protein levels over time."
Price: 1.42, Change: -1.46, Percent Change: -50.76
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.